Live Financial Acquires Disinfectant Company 'CL Pharmtech' in a Surprise Move

[Asia Economy Reporter Hyunseok Yoo] Live Financial announced on the 4th that it has acquired a 50% stake in 'CL Pharmtech,' a virus disinfectant specialist company. Its subsidiary, Gyeongnam Pharmaceutical, also formed a consortium to participate in this acquisition.

The company explained that the purpose of this acquisition is business diversification through entry into new business areas. CL Pharmtech, acquired by Live Financial, was established in 2018 and is developing functional sterilizing disinfectants to prevent and control the spread of avian influenza virus (AI) and foot-and-mouth disease virus.

By supplementing the shortcomings of existing disinfectants with insufficient disinfecting effects, it not only demonstrated high sterilization power in efficacy evaluations conducted by the 'Jeonbuk National University Poultry Disease Control Research Center,' a disinfectant certification institution of the National Institute of Animal Science, but also received high evaluations in disinfectant efficacy.

In particular, CL Pharmtech, which has registered three domestic patents related to AI and foot-and-mouth disease disinfectants, is known to possess strong disinfectant technology in the field of avian influenza.

Meanwhile, Live Financial is the largest shareholder of Gyeongnam Pharmaceutical, a subsidiary of Biogenetics, and has added business purposes such as developing and operating fintech platforms using blockchain, database and online information provision, accelerating its rapidly growing fintech business recently.

This content was produced with the assistance of AI translation services.